Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.

Human Vaccines & Immunotherapeutics
Ibrahim AldossVinod Pullarkat

Abstract

The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably, CD123 is preferentially overexpressed in leukemia stem cells (LSC) in contrast to normal hematopoietic stem cells, and this differential expression allows for the selective eradication of LSC and leukemic blasts through therapeutic targeting of CD123, with less impact on hematopoietic cells. The level of CD123 expression in AML correlates with both treatment response and outcomes. Therefore, targeting CD123 represents a promising universal therapeutic target in advanced acute leukemias irrespective of the individual leukemia phenotype. There are currently 31 ongoing clinical trials examining the utility of CD123-based targeted therapies. Here we focus our review on current efforts to target CD123 in acute leukemia through various therapeutic constructs.

References

Sep 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·O SilvennoinenJ N Ihle
Dec 13, 2003·Leukemia·U TestaC Peschle
Apr 25, 2009·British Journal of Haematology·Francine Garnache-OttouUNKNOWN GOELAMS and GEIL study
Sep 3, 2010·Cytometry. Part B, Clinical Cytometry·Jonathan R Fromm
Oct 18, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wen DuJine Zheng
Jul 14, 2016·Molecular Cancer Therapeutics·Gabriela Hernandez-HoyosJohn W Blankenship
Aug 30, 2016·The Journal of Clinical Investigation·Marco RuellaSaar Gill
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Feb 2, 2018·Frontiers in Immunology·Carlos Cuesta-MateosCecilia Muñoz-Calleja
Apr 25, 2019·The New England Journal of Medicine·Naveen PemmarajuMarina Konopleva
Aug 23, 2019·The Journal of Clinical Investigation·Katsuhiro TogamiAndrew A Lane
Sep 25, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emily Y JenRichard Pazdur

❮ Previous
Next ❯

Citations

Jul 7, 2021·Clinical Lymphoma, Myeloma & Leukemia·Nathaniel R WilsonNaveen Pemmaraju

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
MDS
xenograft

Clinical Trials Mentioned

NCT02113982
NCT03113643
NCT03386513
NCT04086264
NCT02152956
NCT03739606
NCT02730312
NCT02715011
NCT03647800
NCT02159495

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.